Pharmacokinetics of β-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection

Richard FitzGerald; Laura Dickinson; Laura Else; Thomas Fletcher; Colin Hale; Alieu Amara; Lauren Walker; Sujan Dilly Penchala; Rebecca Lyon; Victoria Shaw; William Greenhalf; Katie Bullock; Lara Lavelle-Langham; Helen Reynolds; Wendy Painter; Wayne Holman; Sean Ewings; Gareth Griffiths; Saye Khoo.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21267342

Documentos relacionados

  1. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
  2. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
  3. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
  4. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
  5. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
  6. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
  7. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.
  8. Molnupiravir: an antiviral drug against COVID-19.
  9. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
  10. Characteristics of peripheral white blood cells in COVID-19 patients revealed by a retrospective cohort study.